BACKGROUND: Highly active antiretroviral treatment (HAART) reduces the risk of wasting in HIV infection and may alter the prognostic weight of wasting. The phase angle from bioelectrical impedance analysis (BIA) can be interpreted as a surrogate marker for the catabolic reaction to chronic HIV infection and opportunistic disease. OBJECTIVE: Our objective was to assess the prognostic ability of the phase angle in HIV-infected patients in the era of HAART. DESIGN: Two cross-sectional observation studies were conducted in 1996 and 1997 at a German university outpatient HIV clinic. In the 1996 and 1997 cohorts, HAART was prescribed to 17 of 212 and 168 of 257 patients at baseline and to 179 of 212 and 234 of 257 patients during observation, respectively. Whole-body BIA was assessed at 50 KHz. Time to clinical progression and survival were calculated by using Cox proportional hazard models with time-dependent covariates. Median observation times were 1000 and 515 d for the 1996 and 1997 cohorts, respectively. RESULTS: Higher phase angle was associated with a lower relative mortality risk, adjusted for viral load and CD4(+) cell count, of 0.49 (95% CI: 0.30, 0.81) per degree in 1996 and of 0.33 (95% CI: 0.18, 0.61) in 1997. The influence of phase angle on time to clinical progression, adjusted for viral load and CD4(+) cell count, was not significant in 1996 but the relative risk was 0.58 (0.36, 0.83) in 1997. CONCLUSION: Despite the favorable effects of HAART on the nutritional status of HIV-infected persons, low phase angle remains an independent adverse prognostic marker of clinical progression and survival.
BACKGROUND: Highly active antiretroviral treatment (HAART) reduces the risk of wasting in HIV infection and may alter the prognostic weight of wasting. The phase angle from bioelectrical impedance analysis (BIA) can be interpreted as a surrogate marker for the catabolic reaction to chronic HIV infection and opportunistic disease. OBJECTIVE: Our objective was to assess the prognostic ability of the phase angle in HIV-infectedpatients in the era of HAART. DESIGN: Two cross-sectional observation studies were conducted in 1996 and 1997 at a German university outpatient HIV clinic. In the 1996 and 1997 cohorts, HAART was prescribed to 17 of 212 and 168 of 257 patients at baseline and to 179 of 212 and 234 of 257 patients during observation, respectively. Whole-body BIA was assessed at 50 KHz. Time to clinical progression and survival were calculated by using Cox proportional hazard models with time-dependent covariates. Median observation times were 1000 and 515 d for the 1996 and 1997 cohorts, respectively. RESULTS: Higher phase angle was associated with a lower relative mortality risk, adjusted for viral load and CD4(+) cell count, of 0.49 (95% CI: 0.30, 0.81) per degree in 1996 and of 0.33 (95% CI: 0.18, 0.61) in 1997. The influence of phase angle on time to clinical progression, adjusted for viral load and CD4(+) cell count, was not significant in 1996 but the relative risk was 0.58 (0.36, 0.83) in 1997. CONCLUSION: Despite the favorable effects of HAART on the nutritional status of HIV-infectedpersons, low phase angle remains an independent adverse prognostic marker of clinical progression and survival.
Authors: P Freitas; D Carvalho; A C Santos; J Mesquita; F Correia; S Xerinda; R Marques; E Martinez; A Sarmento; J L Medina Journal: J Endocrinol Invest Date: 2011-07-05 Impact factor: 4.256
Authors: Matthew T Stratton; Robert W Smith; Patrick S Harty; Christian Rodriguez; Baylor A Johnson; Jacob R Dellinger; Abegale D Williams; Sarah J White; Marqui L Benavides; Grant M Tinsley Journal: Eur J Clin Nutr Date: 2021-03-16 Impact factor: 4.016